Genmab AS (FRA:GE91) E10: €0.84 (As of Mar. 2026)


FRA:GE91 Genmab AS FRA:GE91
94 GF Score
Price €22.60
GF Value €30.23
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS E10?

Genmab AS FRA:GE91 94 E10 is €0.84 as of Mar. 2026. GuruFocus rates FRA:GE91 with a GF Score™ of 94/100 and a GF Value™ of €30.23 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genmab AS's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.072. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genmab AS's average E10 Growth Rate was 13.90% per year. During the past 3 years, the average E10 Growth Rate was 22.00% per year. During the past 5 years, the average E10 Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Genmab AS was 558.30% per year. The lowest was 22.00% per year. And the median was 47.45% per year.

As of today (2026-06-29), Genmab AS's current stock price is €22.60. Genmab AS's E10 for the quarter that ended in Mar. 2026 was €0.84. Genmab AS's Shiller PE Ratio of today is 26.90.

During the past 13 years, the highest Shiller PE Ratio of Genmab AS was 21633.33. The lowest was 21.54. And the median was 96.06.


Genmab AS  (FRA:GE91) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genmab AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=22.60/0.84
=26.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Genmab AS was 21633.33. The lowest was 21.54. And the median was 96.06.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Genmab AS E10 Related Terms


Genmab AS E10 Historical Data

* Premium members only.

The historical data trend for Genmab AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS E10 Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.48 0.56 0.73 0.86

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.80 0.86 0.86 0.84

FRA:GE91 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Genmab AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Shiller PE Ratio falls into.


FRA:GE91
94GF Score
Genmab AS FRA:GE91
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.072/121.2000*121.2000
=0.072

Current CPI (Mar. 2026) = 121.2000.

Genmab AS Quarterly Data

per share eps CPI Adj_EPS
201606 0.036 100.600 0.043
201609 0.041 100.200 0.050
201612 0.178 100.300 0.215
201703 0.003 101.200 0.004
201706 0.068 101.200 0.081
201709 -0.001 101.800 -0.001
201712 0.173 101.300 0.207
201803 0.043 101.700 0.051
201806 0.056 102.300 0.066
201809 0.039 102.400 0.046
201812 0.179 102.100 0.212
201903 0.016 102.900 0.019
201906 0.018 102.900 0.021
201909 0.110 102.900 0.130
201912 0.314 102.900 0.370
202003 0.055 103.300 0.065
202006 0.688 103.200 0.808
202009 0.108 103.500 0.126
202012 0.159 103.400 0.186
202103 0.220 104.300 0.256
202106 0.062 105.000 0.072
202109 0.179 105.800 0.205
202112 0.124 106.600 0.141
202203 0.096 109.900 0.106
202206 0.381 113.600 0.406
202209 0.523 116.400 0.545
202212 0.188 115.900 0.197
202303 0.044 117.300 0.045
202306 0.273 116.400 0.284
202309 0.424 117.400 0.438
202312 0.159 116.700 0.165
202403 0.270 118.400 0.276
202406 0.291 118.500 0.298
202409 0.263 118.900 0.268
202412 0.816 118.900 0.832
202503 0.282 120.200 0.284
202506 0.470 120.700 0.472
202509 0.550 121.600 0.548
202512 0.040 121.200 0.040
202603 0.072 121.200 0.072

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.84 mean?
Genmab AS (FRA:GE91) has a E10 of €0.84 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's E10 too high?
Genmab AS's current E10 is €0.84. Overall, Genmab AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's E10 compare to VRTX and REGN?
Genmab AS's E10 of €0.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current E10 is €0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €30.23, compared to a current price of €22.60 — trading 25.2% below its estimated fair value. The current E10 is €0.84. Genmab AS's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current E10 is €0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (FRA:GE91) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €22.60 is trading 25.2% below its estimated GF Value™ of €30.23. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for FRA:GE91:

  • E10: €0.84
  • GF Value™: €30.23 vs. price of €22.60 (25.2% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
94GF Score

Get the complete analysis for FRA:GE91

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.60
Price
€30.23
GF Value